Abstract

Immunological thrombocytopenia (ITP), immune neutropenia, and/or autoimmune haemolytic anaemia (AIHA) can develop concurrently or sequentially in Evans syndrome (ES), an uncommon illness. Frequent relapses, a heavy therapeutic load, and an elevated risk of infection and thrombosis are its hallmarks, all of which have a substantial impact on survival. Several illnesses, including as lymphoproliferative disorders, other systemic autoimmune diseases, and primary immunodeficiencies, can be categorized as primary or secondary to ES. The syndrome has a major influence on survival and quality of life and is frequently severe and sometimes fatal. Effective management of ES requires prompt therapy, including anti-infectious and anti-thrombotic prophylaxis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call